Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours
Latest Information Update: 11 Nov 2026
At a glance
- Drugs 77-Lu RAD 204 (Primary)
- Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Skin cancer; Small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Radiopharm Theranostics
Most Recent Events
- 31 Jul 2026 Results presented in the Radiopharm theranostics media release.
- 22 Jul 2026 Results presented in the Radiopharm theranostics Media Release
- 23 Apr 2026 Results presented in the Radiopharm theranostics media release.